Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Distribution of propensity score by treatment group in the ALLEGRO study

From: Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree

  Treatment group
Placebo Laquinimod 0.6 mg/day
Estimate Estimate
Upper quartile 0.647 0.547
Median 0.540 0.448
Lower quartile 0.445 0.339
Minimum 0.106 0.034